NO20082787L - Rensing og anvendelse av en faktor for a understotte leging av sar - Google Patents

Rensing og anvendelse av en faktor for a understotte leging av sar

Info

Publication number: NO20082787L
Authority: NO; Norway
Prior art keywords: growth factor; factor; wounds; purification; application
Prior art date: 2006-01-25

Application number

NO20082787A

Other languages

English (en)

Norwegian (no)

Inventor

Andrea Neisser-Svae

Stefan Winge

Anna Mjardestam

Original Assignee

Octapharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-01-25

Filing date

2008-06-20

Publication date

2008-10-13

2008-06-20 Application filed by Octapharma Ag filed Critical Octapharma Ag

2008-10-13 Publication of NO20082787L publication Critical patent/NO20082787L/no

Links

206010052428 Wound Diseases 0.000 title 1
208000027418 Wounds and injury Diseases 0.000 title 1
230000035876 healing Effects 0.000 title 1
238000000746 purification Methods 0.000 title 1
102000009024 Epidermal Growth Factor Human genes 0.000 abstract 2
101800003838 Epidermal growth factor Proteins 0.000 abstract 2
102000018233 Fibroblast Growth Factor Human genes 0.000 abstract 2
108050007372 Fibroblast Growth Factor Proteins 0.000 abstract 2
102000003745 Hepatocyte Growth Factor Human genes 0.000 abstract 2
108090000100 Hepatocyte Growth Factor Proteins 0.000 abstract 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 abstract 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 abstract 2
229940116977 epidermal growth factor Drugs 0.000 abstract 2
229940126864 fibroblast growth factor Drugs 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 2
230000029663 wound healing Effects 0.000 abstract 2
NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 abstract 1
108090000935 Antithrombin III Proteins 0.000 abstract 1
102100022977 Antithrombin-III Human genes 0.000 abstract 1
102100023915 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
102000006747 Transforming Growth Factor alpha Human genes 0.000 abstract 1
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
101800004564 Transforming growth factor alpha Proteins 0.000 abstract 1
229960005348 antithrombin iii Drugs 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
238000004140 cleaning Methods 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Toxicology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)

NO20082787A 2006-01-25 2008-06-20 Rensing og anvendelse av en faktor for a understotte leging av sar NO20082787L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06100819		2006-01-25
PCT/EP2007/050714 WO2007085626A1 (en)	2006-01-25	2007-01-25	Purification and use of a factor for supporting wound healing

Publications (1)

Publication Number	Publication Date
NO20082787L true NO20082787L (no)	2008-10-13

Family

ID=36607451

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20082787A NO20082787L (no)	2006-01-25	2008-06-20	Rensing og anvendelse av en faktor for a understotte leging av sar

Country Status (14)

Country	Link
US (1)	US8962813B2 (ru)
EP (1)	EP1987054A1 (ru)
JP (1)	JP2009524622A (ru)
KR (1)	KR20080088610A (ru)
CN (1)	CN101374855A (ru)
AU (1)	AU2007209363B2 (ru)
BR (1)	BRPI0707268A2 (ru)
CA (1)	CA2640010A1 (ru)
IL (1)	IL192320A0 (ru)
NO (1)	NO20082787L (ru)
RU (1)	RU2520817C2 (ru)
UA (1)	UA94442C2 (ru)
WO (1)	WO2007085626A1 (ru)
ZA (1)	ZA200806382B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2357742C1 (ru) *	2008-02-28	2009-06-10	Общество с ограниченной ответственностью "БиоГениус"	Способ получения препарата антитромбина iii из плазмы крови человека
US7935364B2 (en) *	2008-03-04	2011-05-03	Wisconsin Alumni Research Foundation	Patterned gradient wound dressing and methods of using same to promote wound healing
DE102009029194A1 (de) *	2009-09-04	2011-04-07	Kimberly-Clark Worldwide, Inc., Neenah	Abtrennung gefärbter Stoffe aus wasserhaltigen Flüssigkeiten
WO2011028173A1 (en) *	2009-09-05	2011-03-10	Fariba Nayeri	Method of treatment of a patient suffering from an infection or injuries caused or complicated by infection
WO2011150284A2 (en)	2010-05-26	2011-12-01	Baxter International Inc.	Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) *	2010-05-26	2010-09-02	Takeda Pharmaceutical Company Limited	A method to produce an immunoglobulin preparation with improved yield
US8796430B2 (en)	2010-05-26	2014-08-05	Baxter International Inc.	Method to produce an immunoglobulin preparation with improved yield
IL210162A0 (en) *	2010-12-21	2011-03-31	Omrix Biopharmaceuticals	Viral inactivated platelet extract, use and preparation thereof
TR201807926T4 (tr)	2011-02-04	2018-06-21	Octapharma Ag	Koagülasyon faktörlerinin çökeltme yoluyla etkisizleştirilmesine/çıkarılmasına yönelik usul.
WO2013077641A1 (ko) *	2011-11-22	2013-05-30	(주)아모레퍼시픽	성장 인자를 포함하는 피부 재생 촉진제
US9161869B2 (en)	2012-03-30	2015-10-20	Kimberly-Clark Worldwide, Inc.	Absorbent articles with decolorizing agents
US9237975B2 (en)	2013-09-27	2016-01-19	Kimberly-Clark Worldwide, Inc.	Absorbent article with side barriers and decolorizing agents
WO2016137998A1 (en)	2015-02-27	2016-09-01	The University Of Vermont And State Agriculture College	Compositions and methods for vascular protection against reperfusion injury after myocardial ischemia
WO2017025965A1 (en)	2015-08-13	2017-02-16	Kamada Ltd.	Compositions derived from cohn fraction paste and use thereof
CN107216384A (zh) *	2017-05-11	2017-09-29	深圳市卫光生物制品股份有限公司	一种人血浆转铁蛋白分离纯化的方法
US20210087224A1 (en) *	2019-09-20	2021-03-25	Plasma Technologies, Llc	Compositions and methods for generating modified cryo poor plasma
CN114746108A (zh) *	2019-09-20	2022-07-12	等离子体技术有限责任公司	治疗性蛋白质组合物和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6045534A (ja) *	1983-08-22	1985-03-12	Otsuka Pharmaceut Co Ltd	肝実質細胞増殖因子
JPS60243019A (ja) *	1984-05-17	1985-12-03	Mitsubishi Chem Ind Ltd	肝細胞増殖因子
US4673733A (en) *	1985-04-11	1987-06-16	Sudhish Chandra	Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
US4839298A (en) *	1986-02-14	1989-06-13	Akzo N.V.	Virus inactivating diluents used in immunoassays
JP2564486B2 (ja) *	1986-07-14	1996-12-18	修治橋本	肝細胞増殖因子
NZ232813A (en) *	1989-03-10	1992-08-26	Snow Brand Milk Products Co Ltd	Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
GB9110202D0 (en) *	1991-05-10	1991-07-03	Erba Carlo Spa	Truncated forms of the hepatocyte growth factor(hgf)receptor
US5348941A (en) *	1992-04-01	1994-09-20	Merck & Co., Inc.	Stabilizers for fibroblast growth factors
AUPN858596A0 (en) *	1996-03-08	1996-04-04	Csl Limited	Filtration of plasma precipitates using cellulose filter aid
US6451978B2 (en) *	2000-01-21	2002-09-17	Biovitrum Ab	Purification of antithrombin-III-α and β
SE0000178D0 (sv) *	2000-01-21	2000-01-21	Pharmacia & Upjohn Ab	Protein purification I
WO2006138468A2 (en) *	2005-06-17	2006-12-28	Genentech, Inc.	Use of vegf for wound healing

2007
- 2007-01-25 EP EP07726226A patent/EP1987054A1/en not_active Withdrawn
- 2007-01-25 BR BRPI0707268-6A patent/BRPI0707268A2/pt not_active IP Right Cessation
- 2007-01-25 CN CNA2007800029120A patent/CN101374855A/zh active Pending
- 2007-01-25 WO PCT/EP2007/050714 patent/WO2007085626A1/en not_active Ceased
- 2007-01-25 AU AU2007209363A patent/AU2007209363B2/en not_active Ceased
- 2007-01-25 US US12/162,107 patent/US8962813B2/en not_active Expired - Fee Related
- 2007-01-25 UA UAA200810618A patent/UA94442C2/ru unknown
- 2007-01-25 RU RU2008134479/10A patent/RU2520817C2/ru not_active IP Right Cessation
- 2007-01-25 JP JP2008551784A patent/JP2009524622A/ja active Pending
- 2007-01-25 KR KR1020087018153A patent/KR20080088610A/ko not_active Ceased
- 2007-01-25 CA CA002640010A patent/CA2640010A1/en not_active Abandoned
2008
- 2008-06-19 IL IL192320A patent/IL192320A0/en unknown
- 2008-06-20 NO NO20082787A patent/NO20082787L/no not_active Application Discontinuation
- 2008-07-23 ZA ZA200806382A patent/ZA200806382B/xx unknown

Also Published As

Publication number	Publication date
IL192320A0 (en)	2008-12-29
KR20080088610A (ko)	2008-10-02
RU2520817C2 (ru)	2014-06-27
CA2640010A1 (en)	2007-08-02
US8962813B2 (en)	2015-02-24
JP2009524622A (ja)	2009-07-02
ZA200806382B (en)	2009-06-24
UA94442C2 (ru)	2011-05-10
WO2007085626A1 (en)	2007-08-02
CN101374855A (zh)	2009-02-25
US20090221491A1 (en)	2009-09-03
AU2007209363A1 (en)	2007-08-02
EP1987054A1 (en)	2008-11-05
US20100261651A9 (en)	2010-10-14
RU2008134479A (ru)	2010-02-27
BRPI0707268A2 (pt)	2011-04-26
AU2007209363B2 (en)	2013-08-22

Publication	Publication Date	Title
NO20082787L (no)	2008-10-13	Rensing og anvendelse av en faktor for a understotte leging av sar
GB2441939A (en)	2008-03-19	Surgical membrane
MX2012003558A (es)	2012-07-03	Procedimiento para la purificacion de eritropoyetina humana recombinante (epo), epo asi purificada y composiciones farmaceuticas que la comprenden.
AU2009315204A8 (en)	2013-03-28	Additive for differentiation induction culture medium, and use thereof
MX2010008094A (es)	2010-08-04	Endoprotesis/endoprotesis cubierta para refuerzo de anormalidades vasculares y metodo asociado.
NZ593111A (en)	2013-05-31	Antibacterial compounds
MX2008014101A (es)	2008-11-14	Acidos carboxilicos sustituidos con 4,5-difenil-pirimidinilamino, metodo para su produccion y su uso como medicamentos.
BR122017021516B8 (pt)	2021-07-27	processo de preparação de uma estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia
DE602005012905D1 (de)	2009-04-09	Verwendung von Substanz P zur Mobilisierung und Proliferation mesenchymaler Stammzellen und zur Wundheilung
SG169366A1 (en)	2011-03-30	Pharmaceutical composition of microspheres for preventing diabetic foot amputation
MY149648A (en)	2013-09-30	Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
RU2011105821A (ru)	2012-08-27	Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности
CU20130063A7 (es)	2013-06-28	Proceso de producción de depsipéptidos cíclicos
DE50014830D1 (de)	2008-01-17	C-peptid zur verbesserten herstellung von insulin und insulinanaloga
ATE443722T1 (de)	2009-10-15	Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
ATE338539T1 (de)	2006-09-15	Prozess zur herstellung einer sterilen suspension von corticoid-partikeln zur verabreichung durch inhalation
ZA200806112B (en)	2009-10-28	Use of a topical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention
ATE367167T1 (de)	2007-08-15	Aufbereitung von aldesleukin zur pharmazeutischen verwendung
DK1901755T3 (da)	2011-01-10	Nye farmaceutiske sammensætninger indeholdende hyaluronsyre eller dens derivater og collagenase til topisk behandling af sår, forbrændinger og ulcera
MX2008015381A (es)	2009-05-05	Nuevos acidos fosfinicos y sus derivados y metodos para su preparacion.
UA104281C2 (ru)	2014-01-27	Противоопухолевые аналоги пептидов, способ их получения и фармацевтическая композиция на них основе
DE602005020185D1 (de)	2010-05-06	Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4henprodukte für dieses verfahren
WO2006093814A3 (en)	2009-04-16	Fgf growth factor analogs
DE60206499D1 (de)	2006-02-16	Verfahren zur herstellung von d-pantothensäure und/oder salzen davon
FI20045307A0 (fi)	2004-08-25	Kipsilevyn pinnoite ja kipsilevy

Legal Events

Date	Code	Title	Description
2014-08-25	FC2A	Withdrawal, rejection or dismissal of laid open patent application